Aeglea BioTherapeutics Revenue and Competitors

Austin, TX USA

Location

$56M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aeglea BioTherapeutics's estimated annual revenue is currently $3.9M per year.(i)
  • Aeglea BioTherapeutics received $12.3M in venture funding in June 2017.
  • Aeglea BioTherapeutics's estimated revenue per employee is $108,000
  • Aeglea BioTherapeutics's total funding is $56M.

Employee Data

  • Aeglea BioTherapeutics has 36 Employees.(i)
  • Aeglea BioTherapeutics grew their employee count by -63% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6200%N/AN/A
#2
$15.8M10234%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$2.8M18-25%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.6M1550%N/AN/A
#7
$7.6M4923%N/AN/A
#8
$0.9M6-33%N/AN/A
#9
$1.6M10-9%N/AN/A
#10
N/A8662%N/AN/A
Add Company

Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$56M

Total Funding

36

Number of Employees

$3.9M

Revenue (est)

-63%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aeglea BioTherapeutics's People

NameTitleEmail/Phone
1
VP Corporate Development
2
Director Diagnostics and Marketing
3
VP Investor Relations & Corporate Communications
4
Chief Product Officer
5
Financial Analyst
6
General Counsel
7
Director, Product Operations
8
Senior Procurement Manager
9
Chief Financial Officer

Aeglea BioTherapeutics News

2021-08-05 - Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ...

2021-05-06 - Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced the launch of THINK ARGININE, a disease educati ...

2021-02-03 - Aeglea BioTherapeutics Announces Transition of Chief Financial Officer

AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial office ...

2020-12-01 - Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug Admin ...

2019-09-05 - Aeglea BioTherapeutics to Present at 21st Annual HC ...

AUSTIN, Texas, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M36-66%$40M
#2
$6.3M36-20%N/A
#3
$4.2M369%N/A
#4
$6.3M36-35%N/A
#5
$7.3M36N/AN/A

Aeglea BioTherapeutics Funding

DateAmountRoundLead InvestorsReference
2015-03-24$44.0MBLilly VenturesArticle
2017-06-07$12.3MUndisclosedJonesTrading Institutional Services LLCArticle